Trial Profile
Post-Marketing Surveillance of Herceptin Subcutaneous in Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jun 2020
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 04 Jun 2020 Status changed from recruiting to completed.
- 12 Feb 2019 Planned End Date changed from 1 May 2020 to 8 May 2020.
- 12 Feb 2019 Planned primary completion date changed from 1 May 2020 to 8 May 2020.